An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies

Autor: William H. Ludlam, Maria Fleseriu, Leon Fogelfeld, Susan D. Mathias, Jill Sisco, Ross D. Crosby, Murray B. Gordon, Asi Haviv
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Quality of life
Adenoma
Adult
Male
medicine.medical_specialty
Antineoplastic Agents
Hormonal
Endocrinology
Diabetes and Metabolism
Injections
Subcutaneous
Minimal Clinically Important Difference
Disease
Octreotide
Acro-TSQ
Injections
Intramuscular
Peptides
Cyclic
Article
Endocrinology
Patient satisfaction
Surveys and Questionnaires
Acromegaly
Validation
Medicine
Humans
Patient Reported Outcome Measures
Patient reported outcomes
Reliability (statistics)
Netherlands
business.industry
Questionnaire
Reproducibility of Results
Middle Aged
medicine.disease
United Kingdom
United States
Convergent validity
Patient Satisfaction
Delayed-Action Preparations
Physical therapy
Patient-reported outcome
Female
Growth Hormone-Secreting Pituitary Adenoma
business
Factor Analysis
Statistical
Somatostatin
Adverse drug reaction
Measurement properties
Zdroj: Pituitary
ISSN: 1573-7403
1386-341X
Popis: Purpose The Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) is a new patient-reported outcome (PRO) measure for patients with acromegaly receiving injectable somatostatin analogs (SSAs) to assess clinical symptoms and adverse drug reaction interference, treatment satisfaction, and convenience. We evaluated its scale structure, reliability, validity, responsiveness, and what constitutes clinically meaningful change. Methods Data from two longitudinal studies (N = 79 and 82) of patients receiving a stable injectable SSA dose for ≥ 6 months who completed the Acro-TSQ and other collateral measures (e.g., AcroQoL, AIS, WPAI:SHP, EQ-5D-5L) were analyzed. Results The first study demonstrated internal consistency of the Acro-TSQ. However, several items had high ceiling effects, responsiveness could not be established, and the minimally important difference (MID) was not estimable. In the second study, factor analysis revealed six scales: Symptom Interference, Treatment Convenience, Injection Site Interference, GI Interference, Treatment Satisfaction, and Emotional Reaction. Internal consistency and test–retest reliability were confirmed; most scales demonstrated significant differences in mean scores by disease severity. Correlations between Acro-TSQ scales and other collateral measures exceeded 0.30 in absolute value, confirming convergent validity. Responsiveness in Acro-TSQ scale scores reflected improved disease control. The MID was estimated for Symptom Interference (10–12 points), Treatment Convenience (9–11) and GI Interference (8–10). Conclusions The Acro-TSQ is a brief, yet comprehensive tool to monitor important outcomes associated with injectable acromegaly SSA treatments. Its content reflects both disease and treatment burden as well as patient satisfaction, and its relevant for use in clinical studies.
Databáze: OpenAIRE
Externí odkaz: